Literature DB >> 1903526

Preparation of lyophilized heat-treated cryoprecipitates from a small pool of plasma obtained by apheresis.

D P Allersma1, E Roeffen, J A Van der Does, E Briët.   

Abstract

A method was developed for the batch-wise production of small-pool lyophilized heat-treated cryoprecipitates in a regional Blood Bank. Ten vials of final product were derived from twenty 600 g apheresis plasma donations. We found 384 IU of factor VIII per vial and a specific activity of 0.20 IU per mg total protein. Production recovery was 340 IU of factor VIII per kg plasma. The method was easy to perform and gave a product of good quality.

Mesh：

Substances：

Year:  1991        PMID： 1903526     DOI： 10.1007/bf01963879

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN： 0167-6555


  13 in total

1.  Quality control programme for the preparation of small-pool lyophilized heat-treated cryoprecipitates.

Authors:  D P Allersma; F Swüste; E Briët; J A Van der Does
Journal:  Pharm Weekbl Sci       Date:  1991-02-22

2.  Preparation of stable lyophilized cryoprecipitate in the original frozen plasma bags.

Authors:  J Margolis; M Eisen
Journal:  Vox Sang       Date:  1986       Impact factor: 2.144

3.  Heat sterilisation to inactivate AIDS virus in lyophilised factor VIII.

Authors:  J Margolis; Z P Li
Journal:  Aust N Z J Med       Date:  1986-06

4.  Plasma collection using an automated membrane device.

Authors:  G Rock; P Tittley; N McCombie
Journal:  Transfusion       Date:  1986 May-Jun       Impact factor: 3.157

5.  Technical aspects of different donor plasmapheresis systems and biological results obtained in collected plasma.

Authors:  G Vezon; Y Piquet; C Manier; F Schooneman; F Mesnier; J Moulinier
Journal:  Vox Sang       Date:  1986       Impact factor: 2.144

6.  Stabilising effect of aminoacids on factor VIII in lyophilised cryoprecipitate.

Authors:  J Margolis; M Eisen
Journal:  Lancet       Date:  1984-12-08       Impact factor: 79.321

7.  A process for preparation of 'high-purity' factor VIII by controlled pore glass treatment.

Authors:  J Margolis; C M Gallovich; P Rhoades
Journal:  Vox Sang       Date:  1984       Impact factor: 2.144

8.  Plasma separation using a hollow fiber membrane device.

Authors:  D H Buchholz; A Lin; E Snyder; J McCullough; J Porten; M Anderson; J Smith; A Dalmasso; C Helphingstine; M Path
Journal:  Transfusion       Date:  1986 Mar-Apr       Impact factor: 3.157

9.  Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.

Authors:  J S McDougal; L S Martin; S P Cort; M Mozen; C M Heldebrant; B L Evatt
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

10.  Thermal inactivation of human immunodeficiency virus in lyophilised blood products evaluated by ID50 titrations.

Authors:  M Tersmette; R E de Goede; J Over; E de Jonge; H Radema; C J Lucas; H G Huisman; F Miedema
Journal:  Vox Sang       Date:  1986       Impact factor: 2.144
View more
  1 in total

1.  Quality control programme for the preparation of small-pool lyophilized heat-treated cryoprecipitates.

Authors:  D P Allersma; F Swüste; E Briët; J A Van der Does
Journal:  Pharm Weekbl Sci       Date:  1991-02-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.